Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation

References

• Storb R, Yu C, Wagner J L, Deeg H J, Nash R A, Kiem H P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054
   PubMed Web of Science ®Google Scholar
• McSweeney P A, Niederwieser D, Shizuru J A, Sandmaier B M, Molina A J, Maloney D G, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Maris M, Shizuru J A, Petersdorf E, Hegenbart U, Sandmaier B M, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629
   PubMed Web of Science ®Google Scholar
• Diaconescu R, Flowers C R, Storer B, Sorror M L, Maris M B, Maloney D G, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–1558
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin P J, Leisenring W, Flowers M E, Maloney D G, Sandmaier B M, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762
   PubMed Web of Science ®Google Scholar
• Sorror M L, Maris M B, Storer B, Sandmaier B M, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 2004; 104: 961–968
   PubMed Web of Science ®Google Scholar
• van der Jagt R H, Badger C C, Appelbaum F R, Press O W, Matthews D C, Eary J F, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Research 1992; 52: 89–94
   PubMed Web of Science ®Google Scholar
• Andres T L, Kadin M E. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. American Journal of Clinical Pathology 1983; 79: 546–552
   PubMed Web of Science ®Google Scholar
• Caldwell C W, Patterson W P, Hakami N. Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. Leukemia Research 1987; 11: 103–106
   PubMed Web of Science ®Google Scholar
• Matthews D C, Appelbaum F R, Eary J F, Fisher D R, Durack L D, Hui T E, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237–1247
   PubMed Web of Science ®Google Scholar
• Ruffner K L, Matthews D C. Current uses of monoclonal antibodies in the treatment of acute leukemia. Seminars in Oncology 2000; 27: 531–539
   PubMed Web of Science ®Google Scholar
• Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98: 565–572
   PubMed Web of Science ®Google Scholar
• Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leukemia & Lymphoma 2002; 43: 2125–2131
   PubMed Web of Science ®Google Scholar
• Burke J M, Caron P C, Papadopoulos E B, Divgi C R, Sgouros G, Panageas K S, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32: 549–556
   PubMed Web of Science ®Google Scholar
• Ruffner K L, Martin P J, Hussell S, Nourigat C, Fisher D R, Bernstein I D, Matthews D C. Immunosuppressive effects of 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Cancer Research 2001; 61: 5126–5131
   PubMed Web of Science ®Google Scholar
• Macklis R M, Kinsey B M, Kassis A I, Ferrara J L, Atcher R W, Hines J J, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988; 240: 1024–1026
   PubMed Web of Science ®Google Scholar
• McDevitt M R, Sgouros G, Finn R D, Humm J L, Jurcic J G, Larson S M, Scheinberg D A. Radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine 1998; 25: 1341–1351
   PubMedGoogle Scholar
• Wilbur D S. Potential use of alpha-emitting radionuclides in the treatment of cancer. Antibody, Immunoconjugates, and Radiopharmaceuticals 1991; 4: 85–97
   Google Scholar
• Zalutsky M R, Bigner D D. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncologica 1996; 35: 373–379
   PubMed Web of Science ®Google Scholar
• Zalutsky M R. Targeted radiotherapy of brain tumours. British Journal of Cancer 2004; 90: 1469–1473
   PubMed Web of Science ®Google Scholar
• Kennel S J, Stabin M, Yoriyaz H, Brechbiel M, Mirzadeh S. Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi. Nuclear Medicine Biology 1999; 26: 149–157
   PubMed Web of Science ®Google Scholar
• Milenic D E, Roselli M, Mirzadeh S, Pippin C G, Gansow O A, Colcher D, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biotherapy & Radiopharmacy 2001; 16: 133–146
   PubMed Web of Science ®Google Scholar
• Nikula T K, McDevitt M R, Finn R D, Wu C, Kozak R W, Garmestani K, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 anti- bodies: pharmacokinetics, bioactivity, toxicity and chemistry. Journal of Nuclear Medicine 1999; 40: 166–176
   PubMed Web of Science ®Google Scholar
• Tiffany L J, Dobbs D, Garmestani K. Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing α-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy. Antibody, Immunoconjugates, and Radiopharmaceuticals 1994; 7: 99–115
   Google Scholar
• Kobayashi H, Wu C, Yoo T M, Sun B F, Drumm D, Pastan I, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. Journal of Nuclear Medicine 1998; 39: 829–836
   PubMed Web of Science ®Google Scholar
• Wu C, Kobayashi H, Sun B, Yoo T M, Paik C H, Gansow O A, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorganic Medical Chemistry 1997; 5: 1925–1934
   PubMed Web of Science ®Google Scholar
• Huneke R B, Pippin C G, Squire R A, Brechbiel M W, Gansow O A, Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Research 1992; 52: 5818–5820
   PubMed Web of Science ®Google Scholar
• McDevitt M R, Barendswaard E, Ma D, Lai L, Curcio M J, Sgouros G, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Research 2000; 60: 6095–6100
   PubMed Web of Science ®Google Scholar
• Sgouros G, Ballangrud A M, Jurcic J G, McDevitt M R, Humm J L, Erdi Y E, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. Journal of Nuclear Medicine 1999; 40: 1935–1946
   PubMed Web of Science ®Google Scholar
• Sandmaier B M, Bethge W A, Wilbur D S, Hamlin D K, Santos E B, Brechbiel M W, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100: 318–326
   PubMed Web of Science ®Google Scholar
• Bethge W A, Wilbur D S, Storb R, Hamlin D K, Santos E B, Brechbiel M W, Sandmaier B M. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 2004; 78: 352–359
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Barnett T, Wagner J L, Deeg H J, Nash R A, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131–1136
   PubMed Web of Science ®Google Scholar
• Bosserman L D, Murray C, Takvorian T, Anderson K C, Freedman A S, Fitzsimmons J, et al. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 239–245
   PubMed Web of Science ®Google Scholar
• Butturini A, Seeger R C, Gale R P. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood 1986; 68: 954–956
   PubMed Web of Science ®Google Scholar
• Kikly K, Dennert G. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection. Journal of Immunology 1992; 149: 3489–3494
   PubMed Web of Science ®Google Scholar
• Nakamura H, Gress R E. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation 1990; 49: 453–458
   PubMed Web of Science ®Google Scholar
• Reisner Y, Ben Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proceedings of the National Academy of Sciences (USA) 1986; 83: 4012–4015
   PubMed Web of Science ®Google Scholar
• Xu H, Exner B G, Cramer D E, Tanner M K, Mueller Y M, Ildstad S T. CD8( + ), alphabeta-TCR( + ), and gammadelta-TCR( + ) cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow. Journal of Immunology 2002; 168: 1636–1643
   PubMed Web of Science ®Google Scholar
• Barsoukov A A, Moore P F, Storb R, Santos E B, Sandmaier B M. The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation 1999; 67: 1329–1335
   PubMed Web of Science ®Google Scholar
• Buckner C D, Epstein R B, Rudolph R H, Clift R A, Storb R, Thomas E D. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970; 35: 741–750
   PubMed Web of Science ®Google Scholar
• Matthews D C, Appelbaum F R, Eary J F, Hui T E, Fisher D R, Martin P J, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood 1991; 78: 1864–1874
   PubMed Web of Science ®Google Scholar
• Matthews D C, Badger C C, Fisher D R, Hui T E, Nourigat C, Appelbaum F R, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Research 1992; 52: 1228–1234
   PubMed Web of Science ®Google Scholar
• Behr T M, Behe M, Stabin M G, Wehrmann E, Apostolidis C, Molinet R, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab’ fragments in a human colonic cancer model. Cancer Research 1999; 59: 2635–2643
   PubMed Web of Science ®Google Scholar
• Abbas Rizvi S M, Sarkar S, Goozee G, Allen B J. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Research 2000; 10: 281–289
   PubMed Web of Science ®Google Scholar
• Jurcic J G, Larson S M, Sgouros G, McDevitt M R, Finn R D, Divgi C R, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233–1239
   PubMed Web of Science ®Google Scholar
• Matthews D C, Appelbaum F R, Eary J F, Fisher D R, Durack L D, Bush S A, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85: 1122–1131
   PubMed Web of Science ®Google Scholar
• Bethge W A, Wilbur D S, Storb R, Hamlin D K, Santos E B, Brechbiel M W, et al. Selective T-cell ablation with bismuth-213 labeled anti-TCRab as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101: 5068–5075
   PubMed Web of Science ®Google Scholar
• Bianco J A, Sandmaier B, Brown P A, Badger C, Bernstein I, Eary J, et al. Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a ‘cold’ antibody pretreatment dose on marrow localization. Experimental Hematology 1989; 17: 929–934
   PubMed Web of Science ®Google Scholar
• Rajvanshi P, Shulman H M, Sievers E L, McDonald G B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310–2314
   PubMed Web of Science ®Google Scholar
• Jurcic J G. Antibody therapy for residual disease in acute myelogenous leukemia. Critical Reviews in Oncology & Hematology 2001; 38: 37–45
   PubMed Web of Science ®Google Scholar
• Zalutsky M R, Zhao X G, Alston K L, Bigner D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. Journal of Nuclear Medicine 2001; 42: 1508–1515
   PubMed Web of Science ®Google Scholar
• Turkington T G, Zalutsky M R, Jaszczak R J, Garg P K, Vaidyanathan G, Coleman R E. Measuring astatine-211 distributions with SPECT. Physical Medicine & Biology 1993; 38: 1121–1130
   PubMed Web of Science ®Google Scholar
• Zalutsky M R, Zhao X G, Alston K L, Bigner D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At labelled antibodies for clinical use. Journal of Nuclear Medicine 2001; 42: 1508–1515
   PubMed Web of Science ®Google Scholar
• Zalutsky M R, Narula A S. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Applied Radiation Isotopes 1988; 39: 227–232
   Web of Science ®Google Scholar
• Wilbur D S, Vessella R L, Stray J E, Goffe D K, Blouke K A, Atcher R W. Preparation and evaluation of para-[211At]astatobenzoyl labelled anti-renal cell carcinoma antibody A6H F(ab′)2. In vivo comparison with para-[125I]iodobenzoyl labelled A6H F(ab′)2. Nuclear Medicine Biology 1993; 20: 917–927
   PubMed Web of Science ®Google Scholar
• Wilbur D S, Chyan M K, Hamlin D K, Kegley B B, Risler R, Pathare P M, et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamide and nido-carboranyl compounds. Bioconjugate Chemistry 2004; 15: 203–223
   PubMed Web of Science ®Google Scholar
• Wilbur D S, Chyan M K, Hamlin D K. Investigation of a decaborate(2-) containing conjugate for direct labeling of monoclonal antibodies with At-211. Journal of Nuclear Medicine 2005; 46: 31, (abstract)
   Google Scholar